Media

Reset filters

Public-private partnership tackles major challenges in pain care

Petra Bloms-Funke – Grünenthal Group, Germany

On April 01, 2018 a research project with the name IMI-PainCare was launched by a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organisations and companies from the pharmaceutical industry. The main goal of this initiative is to improve the care of patients suffering from acute or chronic pain through a toolbox created specifically for streamlining the research and development of drugs.

This project consist from three sub-projects across all phases of the pharmaceutical value chain:

  • “Providing standardized consented patient-reported outcome measures” (PROMPT) is the first sub-project, led by Winfried Meissner, University of Jena, and Hiltrud Liedgens, Grünenthal. It is located in a key area of both clinical research and clinical practice and has the patient's perspective in its focus.
  • “Functional pain biomarkers” (BioPain) – the second subproject – is led by Rolf-Detlef Treede, University of Heidelberg, and Keith Phillips, Eli Lilly and Company. It is located in the transition stage from pre-clinical to early clinical development and aims to establish pharmacokinetic/ pharmacodynamic models in healthy humans and rodents.
  • The subproject “Translational research in pelvic pain” (TRiPP) is led by Katy Vincent, University of Oxford, and Jens Nagel, Bayer. It has a special focus on pain related to endometriosis and interstitial cystitis/bladder pain syndrome and is located in clinical practice as well as the early stage of disease understanding to provide a robust pre-clinical environment for drug development. 

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need.

  1. Societal Impact of Pain (SIP)
  2. Public-private partnership tackles major challenges in pain care